Individuals with defects in copper metabolism may soon have more targeted treatment options thanks to a new discovery. A new report that an investigational anticancer-drug, elesclomol, can restore the production of cytochrome oxidase protein complex, a critical copper-dependent enzyme required for mitochondrial energy production.